Ackermans & van Haaren leads EUR 60 million Series B Financing Round for Confo Therapeutics, a Belgian clinical-stage biopharmaceutical company

26 Jul 2024 07:00 CEST

Dear shareholder,

Dear Madam, Dear Sir,

please find attached our press release.

Best regards

Ackermans & van Haaren

Attachment

• Ackermans & van Haaren leads EUR 60 million Series B Financing Round for Confo Therapeutics (press release 26 July 2024)

20240726_PPR_AvH invests in Confo_UK.pdf